oxazoles has been researched along with Cardiovascular Stroke in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (16.67) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Buse, JB; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Mellbin, L; Neal, B; Nicholls, SJ; Nozza, A; Rydén, L; Schrieks, IC; Schwartz, GG; Stähli, BE; Svensson, A; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Tardif, JC; Wedel, H; Weichert, A | 1 |
| Buse, JB; Cannata, R; Grobbee, DE; Henry, RR; Lincoff, AM; Malmberg, K; Neal, B; Nicholls, SJ; Rydén, L; Schwartz, GG; Svensson, A; Tardif, JC; Volz, D; Wedel, H; Weichert, A | 1 |
| Bengus, M; Califf, R; Ditmarsch, M; Erdmann, E; Gerstein, HC; Malmberg, K; Ruilope, L; Schwartz, GG; Svensson, A; Volz, D; Wedel, H | 1 |
| Bajaj, M; Birnbaum, Y; Chen, H; Nanhwan, MK; Qian, J; Ye, Y | 1 |
| Blomeyer, C; Kehl, F; Lange, M; Lazariotto, M; Lotz, C; Pociej, J; Redel, A; Roewer, N; Schmidt, J; Smul, TM; Stumpner, J; Tischer-Zeitz, T | 1 |
| Jin, D; Miyazaki, M; Muramatsu, M; Okamoto, Y; Sakaguchi, M; Takai, S | 1 |
| Ciammaichella, A | 1 |
| Agostinelli, MC; Amadio, E; Conti, V; Ganzetti, S; Melappioni, A; Palermo, R; Racco, F | 1 |
| Gomoll, AW; Ogletree, ML; Schumacher, WA | 1 |
| Lada, W | 1 |
1 review(s) available for oxazoles and Cardiovascular Stroke
| Article | Year |
|---|---|
[Imidazoline receptors and use of drug blocking receptors I1].
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Antihypertensive Agents; Arrhythmias, Cardiac; Cimetidine; Histamine H2 Antagonists; Humans; Hypertension; Imidazoles; Myocardial Infarction; Oxazoles; Rilmenidine | 1996 |
4 trial(s) available for oxazoles and Cardiovascular Stroke
| Article | Year |
|---|---|
Adiponectin, Free Fatty Acids, and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adiponectin; Aged; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fatty Acids, Nonesterified; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles; Retrospective Studies; Stroke; Thiophenes; Treatment Outcome | 2018 |
Evaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial.
Topics: Acute Coronary Syndrome; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hospitalization; Humans; Male; Middle Aged; Morbidity; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk Factors; Stroke; Thiophenes; Treatment Outcome | 2013 |
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial.
Topics: Acute Coronary Syndrome; Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Kidney; Male; Middle Aged; Myocardial Infarction; Oxazoles; Peroxisome Proliferator-Activated Receptors; Risk; Stroke; Survival Analysis; Thiophenes; Treatment Outcome | 2014 |
Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Topics: Aged; Cardiovascular Diseases; Cerebrovascular Disorders; Coronary Disease; Diabetes Mellitus, Type 2; Double-Blind Method; Early Termination of Clinical Trials; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Middle Aged; Myalgia; Myocardial Infarction; Myositis; Oxazoles; Peripheral Arterial Disease; PPAR alpha; PPAR gamma; Prediabetic State; Stroke; Thiophenes; Treatment Outcome | 2015 |
7 other study(ies) available for oxazoles and Cardiovascular Stroke
| Article | Year |
|---|---|
Aleglitazar, a Balanced Dual PPARα and -γ Agonist, Protects the Heart Against Ischemia-Reperfusion Injury.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cardiovascular Agents; Cell Survival; Diabetes Mellitus, Experimental; Heart; Humans; Male; Mice; Myocardial Infarction; Myocardial Reperfusion Injury; Myocardium; Myocytes, Cardiac; Oxazoles; PPAR alpha; PPAR gamma; Protective Agents; Signal Transduction; Thiophenes | 2016 |
Activation of peroxisome-proliferator-activated receptors α and γ mediates remote ischemic preconditioning against myocardial infarction in vivo.
Topics: Anilides; Animals; Ischemic Preconditioning, Myocardial; Male; Myocardial Infarction; Myocardial Reperfusion Injury; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Oxazoles; PPAR alpha; PPAR gamma; Prostaglandin D2; Rabbits; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tyrosine | 2011 |
An antiarrhythmic effect of a chymase inhibitor after myocardial infarction.
Topics: Animals; Anti-Arrhythmia Agents; Chymases; Dogs; Enzyme Inhibitors; Humans; Myocardial Infarction; Oxazoles; Serine Endopeptidases; Sulfonamides | 2004 |
A bumpy road to breakthroughs. The news: it's hard to beat today's cardiac treatments.
Topics: Animals; Atherosclerosis; Coronary Thrombosis; Diabetes Mellitus, Type 2; Ethics, Clinical; Glycine; Heart Failure; Humans; Indoleacetic Acids; Myocardial Infarction; Oxazoles; Prostheses and Implants; Stroke; Treatment Failure; Ultrasonography | 2006 |
[Weather changes, psychosomatic alterations and myocardial infarct].
Topics: Adrenergic beta-Antagonists; Humans; Myocardial Infarction; Oxazoles; Psychophysiologic Disorders; Stress, Psychological; Tranquilizing Agents; Weather | 1980 |
[Treatment with sulfinpyrazone in comparison with ditazol. Use of dynamic ECG for the study of the cardiac rhythm in patients with recent acute myocardial infarction].
Topics: Adult; Aged; Electrocardiography; Female; Humans; Male; Middle Aged; Myocardial Infarction; Oxazoles; Sulfinpyrazone | 1983 |
Dose-related cardioprotection by ifetroban in relation to inhibition of thrombosis and ex vivo platelet function.
Topics: Animals; Blood Platelets; Bridged Bicyclo Compounds, Heterocyclic; Dose-Response Relationship, Drug; Ferrets; Hemodynamics; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Neutrophil Activation; Oxazoles; Platelet Aggregation Inhibitors; Propionates; Receptors, Thromboxane; Thrombosis | 1995 |